Sleep apnea: treatments targeting GLP-1 appear to reduce respiratory events

Six trials, two treatments studied

The review includes 1,069 participants: four trials assess liraglutide and two assess tirzepatide. The authors searched for studies and registered trials through February 10, 2025. The source material provides access only to the PubMed abstract, not the full text.

The researchers assessed measures including the apnea-hypopnea index, weight, nighttime oxygenation, blood pressure and adverse events. The abstract specifies neither the duration of each trial nor the exact control group conditions. This information is missing, limiting a full assessment of how the findings apply to an individual situation.

On average, around ten fewer respiratory events per hour

Compared with the control groups, the treatments are associated with an average reduction in the apnea-hypopnea index of 9.99 events per hour. The 95% confidence interval ranges from 3.50 to 16.47 fewer events per hour. This index measures the frequency of interruptions or reductions in breathing during sleep; it does not, on its own, capture all the consequences of the condition.

The average difference in weight is 9.68 kg in favor of the treatments, with a confidence interval ranging from 3.51 to 15.84 kg. However, heterogeneity is substantial: I² reaches 87% for the apnea-hypopnea index and 98% for weight. These averages therefore summarize very different results across trials, rather than a predictable individual benefit.

Improvement does not extend to every measure

The review also reports a reduction in blood pressure. However, it finds no statistically significant difference in the oxygen desaturation index or minimum oxygen saturation. Fewer apneas and hypopneas therefore do not translate here into a demonstrated improvement in all oxygenation measures.

The reduction in weight accompanies the reduction in respiratory events, but the abstract does not allow us to determine how much of the benefit is mediated by weight loss. Nor does it allow these findings to be extended to all drugs targeting GLP-1.

A possible role in care, not a replacement for CPAP

The authors consider these treatments as part of comprehensive care for obstructive sleep apnea. They specify that their findings do not establish them as substitutes for CPAP. This study therefore does not justify stopping a prescribed treatment.

The abstract reports no increase in the risk of adverse events. This does not mean there are no risks: detailed events, excluded populations and follow-up durations are not available in the source material. Funding and conflicts of interest could not be verified either.

What we can take away

These trials suggest a reduction in apneas and hypopneas with liraglutide or tirzepatide in the populations studied. The magnitude of the benefit remains uncertain, and no replacement for CPAP has been demonstrated.